Icares Medicus, Inc. (6612.TWO) Stock

6612.TWO logo

Icares Medicus, Inc.

6612.TWOTaiwan
Healthcare

Company profile

Icares Medicus reported revenue of 1.13 billion TWD for fiscal year 2025, and net income of 51.23 million TWD. That is a net profit margin of 4.5% for fiscal year 2025. Its largest business segment, Europe and America, brought in 65% of segment revenue in fiscal year 2025; United States was the largest region with 30%. Our analysis of its filings shows revenue growing from 605.45 million TWD in fiscal year 2023 to 1.13 billion TWD in fiscal year 2025, 36.7% a year on average.

What stands out

  • Revenue rose 31.5% in fiscal year 2025, from 859.79 million TWD in fiscal year 2024, after a rise of 42.0% the year before.
  • Net income fell 50.3% in fiscal year 2025, from 103.12 million TWD in fiscal year 2024.

Figures from company filings; latest fiscal year ended December 31, 2025.

About Icares Medicus, Inc.

ICARES Medicus, Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of ophthalmic medical devices in Taiwan, the United States, United Kingdom, Japan, Spain, China, Germany, and internationally. The company is also involved in the manufacturing, sales, and service of intraocular lenses (IOLs) and its implantation systems for use in treating cataracts, myopia, farsightedness, presbyopia, or astigmatism, as well as related technical services. In addition, it offers artificial crystal products; and lubricious implantable and invasive high-end nanomedicine material. Further, the company engages in molding, mold design, and development; production of medical devices and electronic plastic products; and distribution of ophthalmic medical equipment. ICARES Medicus, Inc. was incorporated in 2011 and is based in Zhubei, Taiwan.

Leadership

  • Carl Robert Cummings — President of Major Subsidiary
  • Wen-Chu Tseng — Chief R&D Officer & Director
  • Bing Chun Chen — General Manager
  • Tan-Li Chen — VP and Head of Finance & Accounting Department
  • Junming Lin — Vice President of R&D and Operations

How much revenue does Icares Medicus make?

Icares Medicus reported 1.13 billion TWD in revenue for fiscal year 2025, up 31.5% from 859.79 million TWD in fiscal year 2024.

What is Icares Medicus's largest business segment?

Europe and America, with 929.48 million TWD or 65% of segment revenue in fiscal year 2025. Next: Taiwan (34%) and Mainland China (1%).

Where does Icares Medicus make most of its revenue?

United States: 30% of revenue by region in fiscal year 2025, followed by Other (27%).

What companies are similar to Icares Medicus?

Listed companies of a similar size in the same industry (targeted healthcare equipment) include Visco Vision Inc. (6782.TW), Vizionfocus Inc. (4771.TW), St.Shine Optical Co.,Ltd. (1565.TWO), Medimaging Integrated Solution Inc. (6796.TW).

How has Icares Medicus' revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 393.92 million TWD; FY2022, 511.85 million TWD; FY2023, 605.45 million TWD; FY2024, 859.79 million TWD; FY2025, 1.13 billion TWD.

Has Icares Medicus made a profit in recent years?

Net income by fiscal year: FY2021, 58.60 million TWD; FY2022, 128.91 million TWD; FY2023, 97.73 million TWD; FY2024, 103.12 million TWD; FY2025, 51.23 million TWD. It was profitable in each of these years.

Company Information

SectorHealthcare
IndustryTargeted Healthcare Equipment
HeadquartersZhubei, Taiwan
ExchangeTaipei Exchange
TimezoneAsia/Taipei (CST)

Contact & Links

Address
No. 16, Shengyi Road, Zhubei
Phone
886 3 657 9530
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Icares Medicus, Inc. (6612.TWO)”, data as of Dec 31, 2025, https://dataporium.tech/stocks/6612.TWO

LinkedInLinkedInXXYouTubeYouTube